Ultramicronized N-palmitoylethanolamine Contributes to Morphine Efficacy Against Neuropathic Pain: Implication of Mast Cells and Glia
Laboratory studyOther animalsWith morphine
This study tested palmitoylethanolamide together with morphine. Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Laboratory study
- Subjects
- Rats with chronic constriction injury of the sciatic nerve
- Dose used in the study
- Ultramicronised palmitoylethanolamide given before and with morphine at fixed or increasing doses of both; amounts and route not stated in the abstract
- Duration
- Not stated in the abstract
- What was measured
- Pain behaviour and morphine tolerance; spinal microglia and astrocyte activation (Iba-1, GFAP); endoneural mast cells in the sciatic nerve; plasma histamine and N-methyl-histamine.
What the authors reported
The study found:
- Pre-emptive and concurrent ultramicronised PEA lowered the effective dose of morphine and delayed morphine tolerance.
- Spinal glial activation raised by nerve injury or morphine was reduced by PEA.
- Mast cell density in the sciatic nerve fell with PEA, and histamine markers fell mainly at intermediate to high PEA doses.
Limits of this study
A rat model of neuropathic pain; it cannot show effect in people. Doses are not in the abstract. The authors declare no conflict of interest.
Source
PubMed 36443965 · doi:10.2174/1570159X21666221128091453
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.